Program:
Overview of significant clinical aspects presented during the meeting, including:

• Abstract 865: Australian ASCEND study:
  Excellent early and molecular responses observed with Asciminib treatment for CP-CML: Results from the ALLG CML13 ASCEMBL Study (Yeung D et al)
• Abstract 446: Update from the German TIGER trial:
  Treatment-free remission after Nilotinib plus Peg-Interferon α induction and Peg-Interferon α maintenance therapy for newly diagnosed CML patients (Hochhaus A et al)

If you have any questions or comments to the speaker, please email info@cml-foundation.org.

Timestamps:

00:00 Welcome and introduction
02:46 Abstract 865: Australian ASCEND study: Excellent early and molecular responses observed with Asciminib treatment for CP-CML: Results from the ALLG CML13 ASCEMBL Study (Yeung D et al)
12:04 Abstract 446: Update from the German TIGER trial: Treatment-free remission after Nilotinib plus Peg-Interferon α induction and Peg-Interferon α maintenance therapy for newly diagnosed CML patients (Hochhaus A et al)